Macrogenics Inc (NASDAQ: MGNX)’s stock price has increased by 0.60 compared to its previous closing price of 18.24. However, the company has seen a 30.88% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-05 that Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024.
Is It Worth Investing in Macrogenics Inc (NASDAQ: MGNX) Right Now?
Company’s 36-month beta value is 2.07.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MGNX is 58.56M, and currently, short sellers hold a 9.57% ratio of that floaft. The average trading volume of MGNX on April 09, 2024 was 1.58M shares.
MGNX’s Market Performance
MGNX’s stock has seen a 30.88% increase for the week, with a -10.53% drop in the past month and a 87.82% gain in the past quarter. The volatility ratio for the week is 10.32%, and the volatility levels for the past 30 days are at 8.54% for Macrogenics Inc The simple moving average for the past 20 days is 17.52% for MGNX’s stock, with a 104.84% simple moving average for the past 200 days.
Analysts’ Opinion of MGNX
Many brokerage firms have already submitted their reports for MGNX stocks, with BTIG Research repeating the rating for MGNX by listing it as a “Buy.” The predicted price for MGNX in the upcoming period, according to BTIG Research is $24 based on the research report published on March 04, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MGNX reach a price target of $14, previously predicting the price at $12. The rating they have provided for MGNX stocks is “Neutral” according to the report published on February 14th, 2024.
Citigroup gave a rating of “Buy” to MGNX, setting the target price at $13 in the report published on December 20th of the previous year.
MGNX Trading at 11.06% from the 50-Day Moving Average
After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.13% of loss for the given period.
Volatility was left at 8.54%, however, over the last 30 days, the volatility rate increased by 10.32%, as shares surge +5.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.36% upper at present.
During the last 5 trading sessions, MGNX rose by +30.88%, which changed the moving average for the period of 200-days by +221.37% in comparison to the 20-day moving average, which settled at $15.66. In addition, Macrogenics Inc saw 90.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGNX starting from Peters Jeffrey Stuart, who sale 51,395 shares at the price of $15.55 back on Apr 04 ’24. After this action, Peters Jeffrey Stuart now owns 0 shares of Macrogenics Inc, valued at $799,148 using the latest closing price.
Peters Jeffrey Stuart, the Senior VP and General Counsel of Macrogenics Inc, sale 19,625 shares at $21.50 during a trade that took place back on Mar 06 ’24, which means that Peters Jeffrey Stuart is holding 8,895 shares at $421,938 based on the most recent closing price.
Stock Fundamentals for MGNX
Current profitability levels for the company are sitting at:
- -2.86 for the present operating margin
- 0.99 for the gross margin
The net margin for Macrogenics Inc stands at -0.15. The total capital return value is set at -0.69. Equity return is now at value -6.15, with -3.04 for asset returns.
Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.3. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is 117.65.
Currently, EBITDA for the company is -168.24 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 18.23. The receivables turnover for the company is 5.67for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
In a nutshell, Macrogenics Inc (MGNX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
